clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2024-102-9-10-698-706clinmed-945Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESХитиназа-3-подобный белок 1 (CHI3L1, YKL-40) при сердечно-сосудистой патологииChitinase-3-like protein 1 (CHI3L1, YKL-40) in cardiovascular pathologyhttps://orcid.org/0000-0001-5416-8579АлиеваА. М.AlievaA. M.

Алиева Амина Магомедовна — канд. мед. наук, доцент

Москва

Amina M. Alieva — Candidate of Medical Sciences, Associate Professor

Moscow

amisha_alieva@mail.ruhttps://orcid.org/0000-0003-1613-3716ВалиевР. К.ValievR. K.

Валиев Рамиз Камраддинович — канд. мед. наук

Москва

Ramiz K. Valiev — Candidate of Medical Sciences

Moscow

https://orcid.org/0000-0003-0886-6290БайковаИ. Е.BaykovaI. E.

Байкова Ирина Евгеньевна — канд. мед. наук, доцент

Москва

Irina E. Baykova — Candidate of Medical Sciences, Associate Professor

Moscow

https://orcid.org/0000-0002-7181-4680ТепловаН. В.TeplovaN. V.

Теплова Наталья Вадимовна — д-р мед. наук, профессор

Москва

Natalia V. Teplova — Doctor of Medical Sciences, Professor

Moscow

https://orcid.org/0000-0003-3000-0987ШнаховаЛ. М.ShnakhovaL. M.

Шнахова Лидия Мухамедовна — врач

Москва

Lidiya M. Shnakhova — Doctor of Medical Sciences

Moscow

https://orcid.org/0000-0003-1794-9258СарыевМ. Н.SaryevM. N.

Сарыев Мухаммет Нурыевич — врач

Москва

Mukhammet N. Saryev — doctor

Moscow

https://orcid.org/0000-0001-5352-8499КотиковаИ. А.KotikovaI. A.

Котикова Ирина Александровна — студентка,

Москва

Irina A. Kotikova — student

Moscow

https://orcid.org/0000-0003-1699-0881НикитинИ. Г.NikitinI. G.

Никитин Игорь Геннадиевич — д.м.н., профессор

Москва

Igor G. Nikitin — Doctor of Medical Sciences, Professor

Moscow

ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияN.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian FederationRussian FederationГБУЗ «Московский клинический научный центр имени А.С. Логинова Департамента здравоохранения города Москвы»РоссияMoscow Clinical Scientific and Practical Center named after A. S. Loginov of the Department of Health of the City of MoscowRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Russian Federation2024050220251029-10698706Copyright © Алиева А.М., Валиев Р.К., Байкова И.Е., Теплова Н.В., Шнахова Л.М., Сарыев М.Н., Котикова И.А., Никитин И.Г., 20252025Алиева А.М., Валиев Р.К., Байкова И.Е., Теплова Н.В., Шнахова Л.М., Сарыев М.Н., Котикова И.А., Никитин И.Г.Alieva A.M., Valiev R.K., Baykova I.E., Teplova N.V., Shnakhova L.M., Saryev M.N., Kotikova I.A., Nikitin I.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/945

Сердечно-сосудистые заболевания (ССЗ) представляют собой глобальную медицинскую, социальную и экономическую проблему. В настоящее время продолжаются поиск и изучение новых биологических маркеров, которые способны обеспечить раннюю диагностику ССЗ, служить лабораторным инструментом оценки эффективности проводимого лечения или использоваться в качестве прогностических маркеров и критериев стратификации риска. Интерес ученых сосредоточен на изучении хитиназы-3-подобного белка 1 (CHI3L1, YKL-40) при ССЗ. Точные данные о роли CHI3L1 как в норме, так и при патологических состояниях до сих пор остаются не ясными. Имеющиеся данные свидетельствуют о том, что CHI3L1, возможно, регулирует пролиферацию, дифференцировку клеток, программируемую клеточную гибель, а также участвует в эмбриональном развитии, ангиогенезе, воспалительных реакциях, ремоделировании тканей,  и ряде других процессов. Согласно данным проведенных клинических исследований, CHI3L1 является перспективной молекулой, обладающей диагностическим и прогностическим потенциалом при ССЗ. Окончательное подтверждение роли CHI3L1 при сердечно-сосудистой патологии будет получено в результате будущих исследований.

Cardiovascular diseases (CVD) represent a global medical, social, and economic issue. Currently, the search and study of new biological markers that can provide early diagnosis of CVD, serve as laboratory tools for assessing the effectiveness of treatment, or be used as prognostic markers and risk stratification criteria are ongoing. Scientists are particularly interested in studying chitinase-3-like protein 1 (CHI3L1, YKL-40) in relation to CVD. The precise role of CHI3L1 in both normal and pathological conditions remains unclear. Existing data suggest that CHI3L1 may regulate cell proliferation, differentiation, programmed cell death, as well as participate in embryonic development, angiogenesis, inflammatory responses, tissue remodeling, and a number of other processes. According to clinical studies conducted, CHI3L1 is a promising molecule with diagnostic and prognostic potential in CVD. The definitive confirmation of the role of CHI3L1 in cardiovascular pathology will be obtained through future research.

сердечно-сосудистые заболеванияишемическая болезнь сердцабиологический маркерCHI3L1YKL-40cardiovascular diseasesischemic heart diseasebiological markerCHI3L1YKL-40ReferencesRoth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., Baddour L.M. et al. GBD-NHLBI-JACC Global burden of cardiovascular diseases writing group. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 Study. J. Am. Coll. Cardiol. 2020;76(25):2982–3 021. DOI: 10.1016/j.jacc.2020.11.010Roth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., Baddour L.M. et al. GBD-NHLBI-JACC Global burden of cardiovascular diseases writing group. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 Study. J. Am. Coll. Cardiol. 2020;76(25):2982–3 021. DOI: 10.1016/j.jacc.2020.11.010Deng P., Fu Y., Chen M., Wang D., Si L. Temporal trends in inequalities of the burden of cardiovascular disease across 186 countries and territories. Int. J. Equity Health. 2023;22(1):164. DOI: 10.1186/s12939-023-01988-2Deng P., Fu Y., Chen M., Wang D., Si L. Temporal trends in inequalities of the burden of cardiovascular disease across 186 countries and territories. Int. J. Equity Health. 2023;22(1):164. DOI: 10.1186/s12939-023-01988-2Silva S., Fatumo S., Nitsch D. Mendelian randomization studies on coronary artery disease: a systematic review and meta-analysis. Syst. Rev. 2024;13(1):29. DOI: 10.1186/s13643-023-02442-8Silva S., Fatumo S., Nitsch D. Mendelian randomization studies on coronary artery disease: a systematic review and meta-analysis. Syst. Rev. 2024;13(1):29. DOI: 10.1186/s13643-023-02442-8Kim S.J., Mesquita F.C.P., Hochman-Mendez C. New biomarkers for cardiovascular disease. Tex. Heart Inst. J. 2023;50(5):e238178. DOI: 10.14503/THIJ-23-8178Kim S.J., Mesquita F.C.P., Hochman-Mendez C. New biomarkers for cardiovascular disease. Tex. Heart Inst. J. 2023;50(5):e238178. DOI: 10.14503/THIJ-23-8178Голухова Е.З., Теряева Н.Б., Алиева А.М. Натрийуретические пептиды — маркеры и факторы прогноза при хронической сердечной недостаточности. Креативная кардиология. 2007;1– 2:126–136.Goluhova E.Z., Teryaeva N.B., Alieva A.M. Natriuretic peptides — markers and prognostic factors in chronic heart failure. Kreativnaya kardiologiya. 2007;1–2:126–136. (In Russian)].Голухова Е.З., Алиева А.М. Клиническое значение определения натрийуретических пептидов у больных с хронической сердечной недостаточностью. Кардиология и сердечнососудистая хирургия. 2007;47(1):45–51.Goluhova E.Z., Alieva A.M. Clinical signifi cance of determination of natriuretic peptides in patients with chronic heart failure Kardiologiya i serdechno-sosudistaya hirurgiya. 2007;47(1):45–51. (In Russian)].Blazevic N., Rogic D., Pelajic S., Miler M., Glavcic G., Ratkajec V.et al. YKL-40 as a biomarker in various inflammatory diseases: A review. Biochem. Med. (Zagreb). 2024;34(1):010502. DOI: 10.11613/BM.2024.010502Blazevic N., Rogic D., Pelajic S., Miler M., Glavcic G., Ratkajec V.et al. YKL-40 as a biomarker in various infl ammatory diseases: A review. Biochem. Med. (Zagreb). 2024;34(1):010502. DOI: 10.11613/BM.2024.010502Zhang Y., Tian J., Ni J., Wei M., Li T., Shi J. Peripheral blood and cerebrospinal fluid levels of YKL-40 in alzheimer’s disease: a systematic review and meta-analysis. Brain Sci. 2023;13(10):1364. DOI: 10.3390/brainsci13101364Zhang Y., Tian J., Ni J., Wei M., Li T., Shi J. Peripheral blood and cerebrospinal fl uid levels of YKL-40 in alzheimer’s disease: a systematic review and meta-analysis. Brain Sci. 2023;13(10):1364. DOI: 10.3390/brainsci13101364Specjalski K., Romantowski J., Niedoszytko M. YKL-40 as a possible marker of neutrophilic asthma. Front Med. (Lausanne). 2023;10:1115938. DOI: 10.3389/fmed.2023.1115938Specjalski K., Romantowski J., Niedoszytko M. YKL-40 as a possible marker of neutrophilic asthma. Front Med. (Lausanne). 2023;10:1115938. DOI: 10.3389/fmed.2023.1115938Albeltagy E.S., Abdul-Mohymen A.M., Taha D.R.A. Early diagnosis of acute kidney injury by urinary YKL-40 in critically ill patients in ICU: a pilot study. Int. Urol. Nephrol. 2020;52:351–61. DOI: 10.1007/s11255-019-02364-2Albeltagy E.S., Abdul-Mohymen A.M., Taha D.R.A. Early diagnosis of acute kidney injury by urinary YKL-40 in critically ill patients in ICU: a pilot study. Int. Urol. Nephrol. 2020;52:351–61. DOI: 10.1007/s11255-019-02364-2Tizaoui K., Yang J.W., Lee K.H., Kim J.H., Kim M., Yoon S.et al.. The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review. Int. J. Biol. Sci. 2022;18(9):3731–3746. DOI: 10.7150/ijbs.67587Tizaoui K., Yang J.W., Lee K.H., Kim J.H., Kim M., Yoon S.et al.. The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review. Int. J. Biol. Sci. 2022;18(9):3731–3746. DOI: 10.7150/ijbs.67587Deng Y., Li G., Chang D., Su X. YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases. Clin. Chim. Acta. 2020;511:40–46. DOI: 10.1016/j.cca.2020.09.035Deng Y., Li G., Chang D., Su X. YKL-40 as a novel biomarker in cardio-metabolic disorders and infl ammatory diseases. Clin. Chim. Acta. 2020;511:40–46. DOI: 10.1016/j.cca.2020.09.035Luo W., Zhang L., Sheng L., Zhang Z., Yang Z. Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis. Diabetol. Metab. Syndr. 2021;13(1):6. DOI: 10.1186/s13098-021-00624-9Luo W., Zhang L., Sheng L., Zhang Z., Yang Z. Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis. Diabetol. Metab. Syndr. 2021;13(1):6. DOI: 10.1186/s13098-021-00624-9Ünal Çetin E., Kamiş F., Çetin A.U., Beyazit Y., Kekilli M. Serum chitotriosidase and YKL-40 in acute pancreatitis: Reliability as prognostic marker for disease severity and correlation with inflammatory markers. Turk. J. Med. Sci. 2021;51:3038–46. DOI: 10.3906/sag-2106-59Ünal Çetin E., Kamiş F., Çetin A.U., Beyazit Y., Kekilli M. Serum chitotriosidase and YKL-40 in acute pancreatitis: Reliability as prognostic marker for disease severity and correlation with infl ammatory markers. Turk. J. Med. Sci. 2021;51:3038–46. DOI: 10.3906/sag-2106-59Wang S., Hu M., Qian Y., Jiang Z., Shen L., Fu L., Hu Y. CHI3L1 in the pathophysiology and diagnosis of liver diseases. Biomed. Pharmacother. 2020;131:110680. DOI: 10.1016/j.biopha.2020.110680Wang S., Hu M., Qian Y., Jiang Z., Shen L., Fu L., Hu Y. CHI3L1 in the pathophysiology and diagnosis of liver diseases. Biomed. Pharmacother. 2020;131:110680. DOI: 10.1016/j.biopha.2020.110680Yu J.E., Yeo I.J., Han S.B., Yun J., Kim B., Yong Y.J.et al. Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer. Exp. Mol. Med. 2024. DOI: 10.1038/s12276-023-01131-9Yu J.E., Yeo I.J., Han S.B., Yun J., Kim B., Yong Y.J.et al. Signifi cance of chitinase-3-like protein 1 in the pathogenesis of infl ammatory diseases and cancer. Exp. Mol. Med. 2024. DOI: 10.1038/s12276-023-01131-9Mazur M., Zielińska A., Grzybowski M.M., Olczak J., Fichna J. Chitinases and chitinase-like proteins as therapeutic targets in inflammatory diseases, with a special focus on inflammatory bowel diseases. Int. J. Mol. Sci. 2021;22(13):6966. DOI: 10.3390/ijms22136966Mazur M., Zielińska A., Grzybowski M.M., Olczak J., Fichna J. Chitinases and chitinase-like proteins as therapeutic targets in infl ammatory diseases, with a special focus on infl ammatory bowel diseases. Int. J. Mol. Sci. 2021;22(13):6966. DOI: 10.3390/ijms22136966Zhao T., Su Z., Li Y., Zhang X., You Q. Chitinase-3 like-protein-1 function and its role in diseases. Signal Transduct. Target Ther. 2020;5(1):201. DOI: 10.1038/s41392-020-00303-7Zhao T., Su Z., Li Y., Zhang X., You Q. Chitinase-3 like-protein-1 function and its role in diseases. Signal Transduct. Target Ther. 2020;5(1):201. DOI: 10.1038/s41392-020-00303-7Kjaergaard A.D., Nordestgaard B.G., Johansen J.S., Bojesen S.E. Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population. Int. J. Cancer. 2015;137:2696–704. DOI: 10.1002/ijc.29638Kjaergaard A.D., Nordestgaard B.G., Johansen J.S., Bojesen S.E. Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population. Int. J. Cancer. 2015;137:2696–704. DOI: 10.1002/ijc.29638Zhao H., Huang M., Jiang L. Potential roles and future perspectives of chitinase 3-like 1 in macrophage polarization and the development of diseases. Int. J. Mol. Sci. 2023;24(22):16149. DOI: 10.3390/ijms242216149Zhao H., Huang M., Jiang L. Potential roles and future perspectives of chitinase 3-like 1 in macrophage polarization and the development of diseases. Int. J. Mol. Sci. 2023;24(22):16149. DOI: 10.3390/ijms242216149Yeo I.J., Lee C.K., Han S.B., Yun J., Hong J.T. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol. Ther. 2019;203:107394. DOI: 10.1016/j.pharmthera.2019.107394Yeo I.J., Lee C.K., Han S.B., Yun J., Hong J.T. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and infl ammatory diseases. Pharmacol. Ther. 2019;203:107394. DOI: 10.1016/j.pharmthera.2019.107394Liu W., Yang Y.J., An Q. LINC00963 Promotes ovarian cancer proliferation, migration and EMT via the miR-378g/CHI3L1 axis. Cancer Manag. Res. 2020;12:463–473. DOI: 10.2147/CMAR.S229083Liu W., Yang Y.J., An Q. LINC00963 Promotes ovarian cancer proliferation, migration and EMT via the miR-378g/CHI3L1 axis. Cancer Manag. Res. 2020;12:463–473. DOI: 10.2147/CMAR.S229083Kim K.C., Yun J., Son D.J., Kim J.Y., Jung J.K., Choi J.S.et al. kim y.r., song j.k., kim s.y., kang s.k., shin d.h., roh y.s., han s.b., hong j.t. Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1. Theranostics. 2018;8(16):4409–4428. DOI: 10.7150/thno.26467Kim K.C., Yun J., Son D.J., Kim J.Y., Jung J.K., Choi J.S.et al. kim y.r., song j.k., kim s.y., kang s.k., shin d.h., roh y.s., han s.b., hong j.t. Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1. Theranostics. 2018;8(16):4409–4428. DOI: 10.7150/thno.26467Sarma N.J., Tiriveedhi V., Subramanian V., Shenoy S., Crippin J.S., Chapman W.C., Mohanakumar T. Hepatitis C virus mediated changes in miRNA-449a modulates inflammatory biomarker YKL40 through components of the NOTCH signaling pathway. PLoS One. 2012;7(11):e50826. DOI: 10.1371/journal.pone.0050826Sarma N.J., Tiriveedhi V., Subramanian V., Shenoy S., Crippin J.S., Chapman W.C., Mohanakumar T. Hepatitis C virus mediated changes in miRNA-449a modulates infl ammatory biomarker YKL40 through components of the NOTCH signaling pathway. PLoS One. 2012;7(11):e50826. DOI: 10.1371/journal.pone.0050826He C.H., Lee C.G., Dela Cruz C.S., Lee C.M., Zhou Y., Ahangari F. et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep. 2013;4(4):830–41. DOI: 10.1016/j.celrep.2013.07.032He C.H., Lee C.G., Dela Cruz C.S., Lee C.M., Zhou Y., Ahangari F. et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep. 2013;4(4):830–41. DOI: 10.1016/j.celrep.2013.07.032Low D., Subramaniam R., Lin L., Aomatsu T., Mizoguchi A., Ng A.et al. Chitinase 3-like 1 induces survival and proliferation of intestinal epithelial cells during chronic inflammation and colitis-associated cancer by regulating S100A9. Oncotarget. 2015;6(34):36535– 50. DOI: 10.18632/oncotarget.5440Low D., Subramaniam R., Lin L., Aomatsu T., Mizoguchi A., Ng A.et al. Chitinase 3-like 1 induces survival and proliferation of intestinal epithelial cells during chronic infl ammation and colitis-associated cancer by regulating S100A9. Oncotarget. 2015;6(34):36535– 50. DOI: 10.18632/oncotarget.5440Francescone R.A., Scully S., Faibish M., Taylor S.L., Oh D., Moral L. et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J. Biol. Chem. 2011;286(17):15332–43. DOI: 10.1074/jbc.M110.212514Francescone R.A., Scully S., Faibish M., Taylor S.L., Oh D., Moral L. et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J. Biol. Chem. 2011;286(17):15332–43. DOI: 10.1074/jbc.M110.212514George L., Mitra A., Thimraj T.A., Irmler M., Vishweswaraiah S., Lunding L.et al. Transcriptomic analysis comparing mouse strains with extreme total lung capacities identifies novel candidate genes for pulmonary function. Respir. Res. 2017;18(1):152. DOI: 10.1186/s12931-017-0629-3George L., Mitra A., Thimraj T.A., Irmler M., Vishweswaraiah S., Lunding L.et al. Transcriptomic analysis comparing mouse strains with extreme total lung capacities identifi es novel candidate genes for pulmonary function. Respir. Res. 2017;18(1):152. DOI: 10.1186/s12931-017-0629-3Parkin G.M., Kim S., Mikhail A., Malhas R., McMillan L., Hollearn M. et al. Associations between saliva and plasma cytokines in cognitively normal, older adults. Aging Clin. Exp. Res. 2023;35:117– 26. DOI: 10.1007/s40520-022-02292-9Parkin G.M., Kim S., Mikhail A., Malhas R., McMillan L., Hollearn M. et al. Associations between saliva and plasma cytokines in cognitively normal, older adults. Aging Clin. Exp. Res. 2023;35:117– 26. DOI: 10.1007/s40520-022-02292-9Llorens F., Thüne K., Tahir W., Kanata E., Diaz-Lucena D., Xanthopoulos K.et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol. Neurodegener. 2017;12:83. DOI: 10.1186/s13024-017-0226-4Llorens F., Thüne K., Tahir W., Kanata E., Diaz-Lucena D., Xanthopoulos K.et al. YKL-40 in the brain and cerebrospinal fl uid of neurodegenerative dementias. Mol. Neurodegener. 2017;12:83. DOI: 10.1186/s13024-017-0226-4Schmalenberg M., Beaudoin C., Bulst L., Steubl D., Luppa P.B. Magnetic bead fluorescent immunoassay for the rapid detection of the novel inflammation marker YKL40 at the point-of-care. J. Immunol. Methods. 2015;427:36–41. DOI: 10.1016/j.jim.2015.09.004Schmalenberg M., Beaudoin C., Bulst L., Steubl D., Luppa P.B. Magnetic bead fl uorescent immunoassay for the rapid detection of the novel infl ammation marker YKL40 at the point-of-care. J. Immunol. Methods. 2015;427:36–41. DOI: 10.1016/j.jim.2015.09.004Bojesen S.E., Johansen J.S., Nordestgaard B.G. Plasma YKL-40 levels in healthy subjects from the general population. Clin. Chim. Acta. 2011;412(9–10):709–12. DOI: 10.1016/j.cca.2011.01.022Bojesen S.E., Johansen J.S., Nordestgaard B.G. Plasma YKL-40 levels in healthy subjects from the general population. Clin. Chim. Acta. 2011;412(9–10):709–12. DOI: 10.1016/j.cca.2011.01.022Cao Y., Gao S., Luo G., Zhao S.Y., Tang Y.Q., Du Z.H., Pan S.L. Role and mechanisms of CHI3L1 in coronary artery lesions in a mouse model of Kawasaki disease-like vasculitis. Zhongguo Dang Dai Er Ke Za Zhi. 2023;25(12):1227–1233. DOI: 10.7499/j.issn.1008-8830.2309080Cao Y., Gao S., Luo G., Zhao S.Y., Tang Y.Q., Du Z.H., Pan S.L. Role and mechanisms of CHI3L1 in coronary artery lesions in a mouse model of Kawasaki disease-like vasculitis. Zhongguo Dang Dai Er Ke Za Zhi. 2023;25(12):1227–1233. DOI: 10.7499/j.issn.1008-8830.2309080Chen L., Zheng J., Xue Q., Zhao Y. YKL-40 promotes the progress of atherosclerosis independent of lipid metabolism in apolipoprotein E-/- mice fed a high-fat diet. Heart Vessels. 2019;34(11):1874–1881. DOI: 10.1007/s00380-019-01434-wChen L., Zheng J., Xue Q., Zhao Y. YKL-40 promotes the progress of atherosclerosis independent of lipid metabolism in apolipoprotein E-/- mice fed a high-fat diet. Heart Vessels. 2019;34(11):1874–1881. DOI: 10.1007/s00380-019-01434-wSun Y., Shan X., Guo J., Liu X., Ma D. CHI3L1 promotes myocardial fibrosis via regulating lncRNA TUG1/miR-495-3p/ETS1 axis. Apoptosis. 2023;28(9–10):1436–1451. DOI: 10.1007/s10495-023-01859-9Sun Y., Shan X., Guo J., Liu X., Ma D. CHI3L1 promotes myocardial fi brosis via regulating lncRNA TUG1/miR-495-3p/ETS1 axis. Apoptosis. 2023;28(9–10):1436–1451. DOI: 10.1007/s10495-023-01859-9Sun X., Nakajima E., Norbrun C., Sorkhdini P., Yang A.X., Yang D. et al. Chitinase 3 like 1 contributes to the development of pulmonary vascular remodeling in pulmonary hypertension. JCI Insight. 2022;7(18):e159578. DOI: 10.1172/jci.insight.159578Sun X., Nakajima E., Norbrun C., Sorkhdini P., Yang A.X., Yang D. et al. Chitinase 3 like 1 contributes to the development of pulmonary vascular remodeling in pulmonary hypertension. JCI Insight. 2022;7(18):e159578. DOI: 10.1172/jci.insight.159578Deng Y., Cai L., Wang F., Huang J., Wang H., Li L., Lv H. Upregulated microRNA-381-5p strengthens the effect of dexmedetomidine preconditioning to protect against myocardial ischemia-reperfusion injury in mouse models by inhibiting CHI3L1. Int. Immunopharmacol. 2021;92:107326. DOI: 10.1016/j.intimp.2020.107326Deng Y., Cai L., Wang F., Huang J., Wang H., Li L., Lv H. Upregulated microRNA-381-5p strengthens the eff ect of dexmedetomidine preconditioning to protect against myocardial ischemia-reperfusion injury in mouse models by inhibiting CHI3L1. Int. Immunopharmacol. 2021;92:107326. DOI: 10.1016/j.intimp.2020.107326Xu T., Zheng X., Wang A., Guo Z., Zhang Y. Association of CHI3L1 gene variants with YKL-40 levels and hypertension incidence: A population-based nested case-control study in China. J. Cell. Mol. Med. 2021;25(2):919–924. DOI: 10.1111/jcmm.16148Xu T., Zheng X., Wang A., Guo Z., Zhang Y. Association of CHI3L1 gene variants with YKL-40 levels and hypertension incidence: A population-based nested case-control study in China. J. Cell. Mol. Med. 2021;25(2):919–924. DOI: 10.1111/jcmm.16148Çetin M., Erdoğan T., Kırış T., Özer S., Çinier G., Emlek N., Durak H., Şatıroğlu Ö. Elevated serum YKL40 level is a predictor of MACE during the long-term follow up in hypertensive patients. Clin. Exp. Hypertens. 2020;42(3):271–274. DOI: 10.1080/10641963.2019.1632342Çetin M., Erdoğan T., Kırış T., Özer S., Çinier G., Emlek N., Durak H., Şatıroğlu Ö. Elevated serum YKL40 level is a predictor of MACE during the long-term follow up in hypertensive patients. Clin. Exp. Hypertens. 2020;42(3):271–274. DOI: 10.1080/10641963.2019.1632342Ridker P.M., Chasman D.I., Rose L., Loscalzo J., Elias J.A. Plasma levels of the proinflammatory chitin-binding glycoprotein YKL-40, variation in the chitinase 3-like 1 gene (CHI3L1), and incident cardiovascular events. J. Am. Heart Assoc. 2014;3(3):e000897. DOI: 10.1161/JAHA.114.000897Ridker P.M., Chasman D.I., Rose L., Loscalzo J., Elias J.A. Plasma levels of the proinfl ammatory chitin-binding glycoprotein YKL-40, variation in the chitinase 3-like 1 gene (CHI3L1), and incident cardiovascular events. J. Am. Heart Assoc. 2014;3(3):e000897. DOI: 10.1161/JAHA.114.000897Kwon Y., Kim J.H., Ha E.K., Jee H.M., Baek H.S., Han M.Y., Jeong S.J. Serum YKL-40 Levels Are Associated with the Atherogenic Index of Plasma in Children. Mediators Inflamm. 2020;2020:8713908. DOI: 10.1155/2020/8713908Kwon Y., Kim J.H., Ha E.K., Jee H.M., Baek H.S., Han M.Y., Jeong S.J. Serum YKL-40 Levels Are Associated with the Atherogenic Index of Plasma in Children. Mediators Infl amm. 2020;2020:8713908. DOI: 10.1155/2020/8713908Song M., Zhang G., Shi H., Zhu E., Deng L., Shen H. Serum YKL-40 in coronary heart disease: linkage with inflammatory cytokines, artery stenosis, and optimal cut-off value for estimating major adverse cardiovascular events. Front Cardiovasc. Med. 2023;10:1242339. DOI: 10.3389/fcvm.2023.1242339Song M., Zhang G., Shi H., Zhu E., Deng L., Shen H. Serum YKL-40 in coronary heart disease: linkage with infl ammatory cytokines, artery stenosis, and optimal cut-off value for estimating major adverse cardiovascular events. Front Cardiovasc. Med. 2023;10:1242339. DOI: 10.3389/fcvm.2023.1242339Zheng J.L., Lu L., Hu J., Zhang R.Y., Zhang Q., Chen Q.J., Shen W.F. Genetic polymorphisms in chitinase 3-like 1 (CHI3L1) are associated with circulating YKL-40 levels, but not with angiographic coronary artery disease in a Chinese population. Cytokine. 2011;54:51–5. DOI: 10.1016/j.cyto.2010.12.018Zheng J.L., Lu L., Hu J., Zhang R.Y., Zhang Q., Chen Q.J., Shen W.F. Genetic polymorphisms in chitinase 3-like 1 (CHI3L1) are associated with circulating YKL-40 levels, but not with angiographic coronary artery disease in a Chinese population. Cytokine. 2011;54:51–5. DOI: 10.1016/j.cyto.2010.12.018Dieden A., Malan L., Mels C.M.C., Lammertyn L., Wentzel A., Nilsson P.M., Gudmundsson P., Jujic A., Magnusson M. Exploring biomarkers associated with deteriorating vascular health using a targeted proteomics chip: The SABPA study. Medicine (Baltimore). 2021;100:e25936. DOI: 10.1097/MD.0000000000025936Dieden A., Malan L., Mels C.M.C., Lammertyn L., Wentzel A., Nilsson P.M., Gudmundsson P., Jujic A., Magnusson M. Exploring biomarkers associated with deteriorating vascular health using a targeted proteomics chip: The SABPA study. Medicine (Baltimore). 2021;100:e25936. DOI: 10.1097/MD.0000000000025936Wallentin L., Eriksson N., Olszowka M., Grammer T.B., Hagström E., Held C. et al. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. PLoS Med. 2021;18(1):e1003513. DOI: 10.1371/journal.pmed.1003513Wallentin L., Eriksson N., Olszowka M., Grammer T.B., Hagström E., Held C. et al. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. PLoS Med. 2021;18(1):e1003513. DOI: 10.1371/journal.pmed.1003513Fang C., Chen Z., Zhang J., Pan J., Jin X., Yang M., Huang L. The value of serum YKL-40 and TNF-α in the diagnosis of acute ST-segment elevation myocardial infarction. Cardiol. Re.s Pract. 2022;2022:4905954. DOI: 10.1155/2022/4905954Fang C., Chen Z., Zhang J., Pan J., Jin X., Yang M., Huang L. The value of serum YKL-40 and TNF-α in the diagnosis of acute ST-segment elevation myocardial infarction. Cardiol. Re.s Pract. 2022;2022:4905954. DOI: 10.1155/2022/4905954Tan Y., Ji X., Mo Z., Zhou Y. Serum YKL-40 positively correlates with MMP-9 and CRP in patients with acute ST segment elevation myocardial infarction following emergency treatment. Medicine (Baltimore). 2019;98(47):e17950. DOI: 10.1097/MD.0000000000017950Tan Y., Ji X., Mo Z., Zhou Y. Serum YKL-40 positively correlates with MMP-9 and CRP in patients with acute ST segment elevation myocardial infarction following emergency treatment. Medicine (Baltimore). 2019;98(47):e17950. DOI: 10.1097/MD.0000000000017950Yang L., Dong H., Lu H., Liao Y., Zhang H., Xu L. et al. Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Medicine (Baltimore). 2019;98(12):e14920. DOI: 10.1097/MD.0000000000014920Yang L., Dong H., Lu H., Liao Y., Zhang H., Xu L. et al. Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Medicine (Baltimore). 2019;98(12):e14920. DOI: 10.1097/MD.0000000000014920Bouwens E., van den Berg V.J., Akkerhuis K.M., Baart S.J., Caliskan K., Brugts J.J. et al. Circulating biomarkers of cell adhesion predict clinical outcome in patients with chronic heart failure. J. Clin. Med. 2020;9(1):195. DOI: 10.3390/jcm9010195Bouwens E., van den Berg V.J., Akkerhuis K.M., Baart S.J., Caliskan K., Brugts J.J. et al. Circulating biomarkers of cell adhesion predict clinical outcome in patients with chronic heart failure. J. Clin. Med. 2020;9(1):195. DOI: 10.3390/jcm9010195Bolla G.B., Fedele A., Faggiano A., Sala C., Santangelo G,. Carugo S. Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction. BMC Cardiovasc. Disord. 2022;22(1):217. DOI: 10.1186/s12872-022-02647-0Bolla G.B., Fedele A., Faggiano A., Sala C., Santangelo G,. Carugo S. Eff ects of Sacubitril/Valsartan on biomarkers of fi brosis and infl ammation in patients with heart failure with reduced ejection fraction. BMC Cardiovasc. Disord. 2022;22(1):217. DOI: 10.1186/s12872-022-02647-0Arain F., Abraityte A., Bogdanova M., Solberg O.G., Michelsen A.E., Lekva T.et al. YKL-40 (Chitinase-3-Like Protein 1) Serum Levels in aortic stenosis. Circ. Heart Fail. 2020;13(10):e006643. DOI: 10.1161/CIRCHEARTFAILURE.119.006643Arain F., Abraityte A., Bogdanova M., Solberg O.G., Michelsen A.E., Lekva T.et al. YKL-40 (Chitinase-3-Like Protein 1) Serum Levels in aortic stenosis. Circ. Heart Fail. 2020;13(10):e006643. DOI: 10.1161/CIRCHEARTFAILURE.119.006643Tan H., Yao H., Lie Z., Chen G., Lin S., Zhang Y. MicroRNA-30a-5p promotes proliferation and inhibits apoptosis of human pulmonary artery endothelial cells under hypoxia by targeting YKL-40. Mol. Med. Rep. 2019;20(1):236–244. DOI: 10.3892/mmr.2019.10251Tan H., Yao H., Lie Z., Chen G., Lin S., Zhang Y. MicroRNA-30a-5p promotes proliferation and inhibits apoptosis of human pulmonary artery endothelial cells under hypoxia by targeting YKL-40. Mol. Med. Rep. 2019;20(1):236–244. DOI: 10.3892/mmr.2019.10251Kerget B., Özkan H.B., Afşin D.E., Koçak A.O., Laloglu E., Uçar E.Y., Sağlam L. Evaluation of serum YKL-40 level among clinical risk scores for early mortality in acute pulmonary thromboembolism. Clin. Biochem. 2022;108:20–26. DOI: 10.1016/j.clinbiochem.2022.07.003Kerget B., Özkan H.B., Afşin D.E., Koçak A.O., Laloglu E., Uçar E.Y., Sağlam L. Evaluation of serum YKL-40 level among clinical risk scores for early mortality in acute pulmonary thromboembolism. Clin. Biochem. 2022;108:20–26. DOI: 10.1016/j.clinbiochem.2022.07.003Fiedorczuk P., Olszewska E., Rogalska J., Brzóska M.M. Osteoprotegerin, Chitinase 3-like Protein 1, and Cardiotrophin-1 as Potential Biomarkers of Obstructive Sleep Apnea in Adults — A Case-Control Study. Int. J. Mol. Sci. 2023;24(3):2607. DOI: 10.3390/ijms24032607Fiedorczuk P., Olszewska E., Rogalska J., Brzóska M.M. Osteoprotegerin, Chitinase 3-like Protein 1, and Cardiotrophin-1 as Potential Biomarkers of Obstructive Sleep Apnea in Adults — A Case-Control Study. Int. J. Mol. Sci. 2023;24(3):2607. DOI: 10.3390/ijms24032607Cai J., Lyu X., Huang P., Li S., Chen R., Chen Z. et al. Increased levels of CHI3L1 and HA are associated with higher occurrence of liver damage in patients with obstructive sleep apnea. Front Med. (Lausanne). 2022;9:854570. DOI: 10.3389/fmed.2022.854570Cai J., Lyu X., Huang P., Li S., Chen R., Chen Z. et al. Increased levels of CHI3L1 and HA are associated with higher occurrence of liver damage in patients with obstructive sleep apnea. Front Med. (Lausanne). 2022;9:854570. DOI: 10.3389/fmed.2022.854570

The authors declare that there are no conflicts of interest present.